Coherus BioSciences (CHRS) Reports In-Line Q1 EPS
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.51 +2.03%
Revenue Growth %: +91.8%
Financial Fact:
Income/(loss) from operations: 27.38M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +91.8%
Financial Fact:
Income/(loss) from operations: 27.38M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q1 EPS of ($0.25), in-line with the analyst estimate of ($0.25). Revenue for the quarter came in at $12.31 million versus the consensus estimate of $14.43 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Accenture (ACN) spreader of 22700 contracts of August 120 puts and 22200 contracts of August 130 calls as share price down 7.2%
- NewAmsterdam Pharma (NAMS) call put ratio 1 call to 4.8 puts with a focus on 2K contracts of January 25 puts
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
